Am Regent Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AM REGENT, and what generic alternatives to AM REGENT drugs are available?
AM REGENT has seventy-two approved drugs.
There are five US patents protecting AM REGENT drugs.
There are sixty-one patent family members on AM REGENT drugs in thirty-two countries and one hundred and fourteen supplementary protection certificates in fifteen countries.
Summary for Am Regent
| International Patents: | 61 |
| US Patents: | 5 |
| Tradenames: | 66 |
| Ingredients: | 63 |
| NDAs: | 72 |
Drugs and US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | FOSPHENYTOIN SODIUM | fosphenytoin sodium | INJECTABLE;INJECTION | 078277-001 | Aug 6, 2007 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Am Regent | DOPAMINE HYDROCHLORIDE | dopamine hydrochloride | INJECTABLE;INJECTION | 070799-001 | Feb 11, 1987 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Am Regent | FOMEPIZOLE | fomepizole | INJECTABLE;INJECTION | 078368-001 | Dec 14, 2007 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Am Regent | DEXFERRUM | ferric oxyhydroxide | INJECTABLE;INJECTION | 040024-001 | Feb 23, 1996 | 5,624,668 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Am Regent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2385788 | See Plans and Pricing |
| Germany | 10249552 | See Plans and Pricing |
| Spain | 2364136 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Am Regent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0502314 | C300095 | Netherlands | See Plans and Pricing | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| 0454436 | C970015 | Netherlands | See Plans and Pricing | PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927 |
| 0502314 | SPC/GB02/037 | United Kingdom | See Plans and Pricing | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
